Thomas Hwang

Jan 1, 2025 | aao.org | Mike Mott |Thomas Hwang |Suzann Pershing

Clinical Update JAN 01, 2025 By Mike Mott, interviewing Michael F. Chiang, MD; Thomas S. Hwang, MD; and Suzann Pershing, MD The promise of interoperability for image sharing, and why you should insist that your vendors comply with DICOM standards.

Oct 7, 2024 | jamanetwork.com | Thomas Hwang |Aaron S. Kesselheim

Clinical trials of new drugs historically excluded children.

Apr 7, 2024 | jamanetwork.com | Aaron S. Kesselheim |Kerstin N. Vokinger |Thomas Hwang

Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs Renata Iskander, MSc; Hannah Moyer, MSc; Karine Vigneault, BSc; Salaheddin M. Mahmud, MD, PhD; Jonathan Kimmelman, PhD Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization Kerstin N. Vokinger, MD, JD, PhD, LLM; Aaron S.

Apr 4, 2024 | jamanetwork.com | Thomas Hwang |Jerry Avorn |Aaron S. Kesselheim

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies Key PointsQuestion  What is the validity of the molecular targets and clinical benefits of US Food and Drug Administration–approved genome-targeted cancer drugs based on the results of pivotal clinical trials? Findings  In this cohort study, 50 molecular-targeted drugs covering 84 indications were identified.

Sep 7, 2023 | jamanetwork.com | Thomas Hwang |Benjamin Davies |Mark Preston

Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer From 20% to 40% of patients with nonmuscle invasive bladder cancer (NMIBC) experience disease recurrence after bacillus Calmette-Guérin (BCG) treatment.1 Until recently, there was only a single, relatively ineffective, treatment option approved for patients who are ineligible for or decline cystectomy (valrubicin approved in 1998).